Friday, July 4, 2025 7/4/2025

Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophy

Award Number: R44NS141438
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2019
PERIOD OF PERFORMANCE END DATE: 04/30/2027

Group Awards By:

View Award Description

Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophy - Project Summary Gene editing offers an innovative approach for gene correction that can permanently edit the patient’s own DNA. To inform how permanent editing may translate to long-term clinical benefit, durability must be characterized in preclinical animal models. Here a gene editing therapy for Duchenne muscular dystrophy that targets deletion of DMD exons 45-55 to restore the reading frame for 50% of all patients will be assessed in a humanized mouse model. This approach is advantageous because it maintains the normal gene regulation and retains three times more of the protein coding sequence than mini/micro-dystrophin gene replacement approaches for Duchenne. This therapy uses systemic adeno-associated virus delivery of CRISPR/Cas9 to edit DNA in muscles throughout the body. In this study, functional efficacy (through non-invasive muscle function measures), restoration of molecular markers (including dystrophin, the dystrophin-glycoprotein complex, histopathology and blood biomarkers) and pilot toxicity readouts will be compared at 2 months versus 6 months post-dosing. Two different immune suppression regimens and three different dosing levels will be tested in juvenile hDMD del45 mdx mice. This work will clarify the long-term durability of gene editing efficacy and how it is influenced by dosing regimens. Learnings from this proposal will have wide applicability to other gene editing therapies which target post-mitotic tissues. As recommended in FDA Guidance, these data will be included in future IND filings and will help advance development of an innovative gene editing therapy for Duchenne muscular dystrophy to clinical studies and then commercialization.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,321,604 )
2025	2025	MYOGENE BIO LLC	7098 MIRATECH DR STE 120	SAN DIEGO	CA	92121	SAN DIEGO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	4	5/12/2025	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$1,321,604
														Subtotal = $1,321,604

Grand Total All Awards = $1,321,604

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophy

Award Number: R44NS141438

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2019

PERIOD OF PERFORMANCE END DATE: 04/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer